Formulation Development
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
Fate Therapeutics, Inc. recently announced that ONO Pharmaceutical Co., Ltd. (ONO) has exercised its option to FT825/ONO-8250, a multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) T-cell…
Actym Therapeutics Reports Preclinical Data Demonstrating Ability to Generate Anti-Tumor Immunity
Actym Therapeutics recently announced an abstract highlighting detailed in vivo and in vitro preclinical data of its lead candidate, ACTM-838, was accepted for presentation at the Society…
NovaQuest Private Equity Announces Investment In Bend Bioscience to Broaden CoreRx Offering
Bend Bioscience and QHP Capital (the management company for NovaQuest Private Equity) have recently announced plans to invest in a new operation in Bend, OR,…
Exelixis & Catalent Enter New License Agreement for Three Antibody-Drug Conjugate Programs With the Potential to Accelerate Exelixis’ Biologics Pipeline
Exelixis, Inc. and Catalent, Inc. recently announced a new license agreement under which Catalent’s Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs with….
Servier & OSE Immunotherapeutics Announce Completion of Patient Enrollment in the Phase 2a Clinical Trial of OSE-127/S95011 in Primary Sjögren’s Syndrome
Servier and OSE Immunotherapeutics SA recently announced the completion of patient enrollment in the Phase 2a clinical trial evaluating the efficacy and safety of monoclonal…
APEIRON Respiratory Therapies Announces Positive Results From Phase I Trial of Inhaled APN01
APEIRON Respiratory Therapies GmbH recently announced positive final results from a Phase 1 clinical trial of inhaled APN01 (alunacedase alfa), a soluble recombinant version of…
Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial
Inozyme Pharma, Inc. recently announced the first self-administration of INZ-701 in the open-label Phase 2 extension portion of the ongoing Phase 1/2 clinical trial of INZ-701…
TFF Pharmaceuticals Announces Collaboration With Aptar Pharma to Explore & Develop Intranasal Delivery of Dry Powder Vaccines & Dry Powder Therapeutics
TFF Pharmaceuticals, Inc. recently announced a collaboration with Aptar Pharma aimed at developing and testing the administration of dry powder vaccines utilizing….
Jounce Therapeutics Earns Clinical Milestone Payment Under Exclusive License Agreement With Gilead Sciences
Jounce Therapeutics, Inc. recently announced earning a $15-million clinical milestone payment from Gilead Sciences, Inc. under the exclusive license agreement for….
Acumen Publishes Phase 1 Trial Design & Clinical Development Plan for an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. recently announced it published its development rationale and clinical development plan for ACU193, the first clinical-stage monoclonal antibody that selectively targets toxic soluble….
Rhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc. recently announced that setmelanotide received Breakthrough Therapy Designation from the US FDA for the treatment of hypothalamic obesity. The FDA's Breakthrough Therapy…
Processa Successfully Identifies Next-Generation Capecitabine Dosage Regimens for Phase 2B Trial
Processa Pharmaceuticals, Inc. recently announced positive results from its ongoing Next-Generation Capecitabine (NGC) Phase 1B trial. The data collected has allowed Processa to estimate the…
Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies
Eterna Therapeutics Inc. recently announced it has entered into a sponsored research agreement with Michael Andreeff, MD, PhD, Professor of Leukemia at The University of Texas MD Anderson Cancer Center (MD Anderson)…..
Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of a Novel Oral Immune Checkpoint Inhibitor
Teon Therapeutics recently announced the first patient has been treated in its Phase 1/2 clinical trial evaluating the safety and efficacy of TT-816, an oral…
Vaccitech Doses First Patients in Phase 2b Clinical Trial of VTP-300 Immunotherapeutic Candidate
Vaccitech plc recently announced the dosing of the first patients in HBV003, a Phase 2b clinical trial designed to further evaluate the safety and efficacy…
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes & Completion of Phase 1 Healthy Volunteer Portion of Phase 1/2 Study
Biomea Fusion, Inc. recently announced the dosing of the first patient with type 2 diabetes in the Phase 2 portion of COVALENT-111, a Phase 1/2…
WHITEPAPER WORKSHOP - Soft Mist Inhalers
Soft mist inhalers (SMIs) are a versatile technology suitable for the delivery of both small and complex large molecules, optimising lung deposition whilst minimising oropharyngeal deposition…..
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership With Emergent BioSolutions
SAB Biotherapeutics recently announced the company has entered into an exclusive manufacturing services agreement with Emergent BioSolutions Inc. Emergent will provide….
Enteris BioPharma Presents Study of Ovarest® Demonstrating Oral Delivery Comparable to or Exceeding Injectable Leuprolide
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly owned subsidiary of SWK Holdings Corporation…
PLATFORM TECHNOLOGY - Versamune®: A New Generation of Cancer Immunotherapies
Dr. Joe Dervan says the unique ability of Versamune® to modulate and enhance numerous critical steps required for an effective clinically relevant immune response and to be combined with targeted antigens found on tumor cells offers several exciting opportunities to treat a variety of cancers.
